Instructor, Internal Medicine, Ohio State University College of Medicine
Infectious Disease
Dr. Mark E. Lustberg, MD
|
|
Give Review
Mark E. Lustberg works in the field of Infectious Disease. He attended University of Maryland School of Medicine. University of Maryland School of Medicine has a rank of 37 in research and a 52 in primary care He over the years received 1 awards: "CMS Meaningful Use Stage 1 Certification". Mark Lustberg is a published MD. He published 25 publications, including: 'A Novel Histone Deacetylase Inhibitor, AR-42, Reactivates HIV-1 from Chronically and Latently Infected CD4(+) T-cells.' He accepts Medicare.
Publications
- The Epstein-Barr virus lytic protein BZLF1 as a candidate target antigen for vaccine development.
- Human Leukocyte Antigen Type and Posttransplant Lymphoproliferative Disorder.
- The translation inhibitor silvestrol exhibits direct anti-tumor activity while preserving innate and adaptive immunity against EBV-driven lymphoproliferative disease.
- Genetic validation of the protein arginine methyltransferase PRMT5 as a candidate therapeutic target in glioblastoma.
- Beyond the bundle - journey of a tertiary care medical intensive care unit to zero central line-associated bloodstream infections.
- Sustained reduction of central line-associated bloodstream infections in an intensive care unit using a top-down and bottom-up approach.
- The economics of antimicrobial stewardship: the current state of the art and applying the business case model.
- Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphoma.
- Phase 2 trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphoma.
- A dose-finding, pharmacokinetic and pharmacodynamic study of a novel schedule of flavopiridol in patients with advanced solid tumors.
- Phase II randomized study of two regimens of sequentially administered mitomycin C and irinotecan in patients with unresectable esophageal and gastroesophageal adenoca...
- Concerns about "Complicated skin and skin-structure infections and catheter-related bloodstream infections: noninferiority of linezolid in a phase 3 study".
- Shock as a covariate in a study of treatment of methicillin-resistant Staphylococcus aureus bacteremia.
- Effect modification by delta-aminolevulinic acid dehydratase, vitamin D receptor, and nitric oxide synthase gene polymorphisms on associations between patella lead and...
- Effect of physician training on fluoroscopy time during ERCP.
- Febuxostat versus allopurinol for gout.
- Associations of uric acid with polymorphisms in the delta-aminolevulinic acid dehydratase, vitamin D receptor, and nitric oxide synthase genes in Korean lead workers.
- The G(894)-T(894) polymorphism in the gene for endothelial nitric oxide synthase and blood pressure in lead-exposed workers from Korea.
- Associations of patella lead with polymorphisms in the vitamin D receptor, delta-aminolevulinic acid dehydratase and endothelial nitric oxide synthase genes.
- Associations of renal function with polymorphisms in the delta-aminolevulinic acid dehydratase, vitamin D receptor, and nitric oxide synthase genes in Korean lead work...
- Blood lead, blood pressure, and hypertension in perimenopausal and postmenopausal women.
- I know lead exposure is dangerous for children, but what about adults?
- A Novel Histone Deacetylase Inhibitor, AR-42, Reactivates HIV-1 from Chronically and Latently Infected CD4(+) T-cells.
- Blood lead levels and mortality.
Schools
University Of Maryland School Of Medicine
Doctors Specialties
- Infectious Disease Medicine
- Infectious Disease
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
Education
-
Ohio State University Hospital -
Wellspan York Hospital -
University of Maryland School of Medicine
Hospital
-
Ohio State University Wexner Medical Center -
Nationwide Children's Hospital
Drug Facts
| NPI NUMBER | 1104948934 | |
| NPPES Provider LastName | LUSTBERG | |
| NPPES Provider FirstName | MARK | |
| NPPES Provider ZIPCode | 432101240 | |
| NPPES Provider State | OH | |
| Specialty Description | Infectious Disease | |
| Total Claim Count | 405.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1104948934 |
| Last Name Of The Provider | LUSTBERG |
| First Name Of The Provider | MARK |
| View All |
Similar Doctors
|
Dr. Christina T. Liscynesky, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Jose A. Bazan, DO
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Julian J. Goodman, MD |
|
|
Dr. Amber M. Vasquez, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Rana Traboulsi, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Ian M. Baird, MB CHB
This Doctor is OpenDoctor Recommended.
|